Exicure (NASDAQ:XCUR) Issues Earnings Results

Exicure (NASDAQ:XCUR) released its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($18.60) by $18.14, FiscalAI reports.

Exicure Price Performance

Shares of Exicure stock traded up $0.02 during trading on Wednesday, hitting $4.49. The stock had a trading volume of 16,841 shares, compared to its average volume of 33,996. Exicure has a 12 month low of $3.10 and a 12 month high of $14.73. The firm’s fifty day simple moving average is $4.44 and its 200-day simple moving average is $4.66. The stock has a market cap of $28.60 million, a PE ratio of -1.21 and a beta of 4.13.

Analyst Ratings Changes

A number of analysts have issued reports on XCUR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exicure in a report on Monday, December 29th. Wall Street Zen upgraded shares of Exicure to a “hold” rating in a research report on Saturday, January 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.